ARTICLE | Clinical News
Antex reports Phase II data
January 9, 2001 8:00 AM UTC
ANX said data from a double-blind, placebo-controlled U.S. Phase II trial in 25 healthy adults showed a four dose regimen of its oral Campylobacter vaccine had a significant immune response with a ten...